

COVID-19 BIOBANK

In the backdrop of the COVID-19 pandemic, while it is of paramount importance to provide early diagnosis and treatment to all infected individuals, it is also critical to promote research and development for larger public health benefit. For development and validation of new diagnostics, therapeutics or vaccines, access to different kinds of clinical samples from infected patients is an essential requirement. COVID-19 biosamples are very important resource for research & development for diagnostics, therapeutics and in vaccine development.

National Liver Disease Biobank (NLDB) at Institute of Liver & Biliary Sciences, New Delhi have been identified by Govt. of India for collecting, storing and maintaining clinical samples (oropharyngeal/ nasopharyngeal swabs, bronchoalveolar lavage, sputum, blood, urine and stool) of COVID-19 patients. In addition, NLDB is also authorised to share the samples with academia, industry and commercial entities involved in development of diagnostics, therapeutics, vaccines etc., after scrutinising the purpose of the request and ensuring benefit to the country.

The COVID-19 biobank at NLDB is an open facility for the researchers across India as per the notification of the Government of India, Ministry of Home Affairs order no. “[40-3/2020-DM-I \(A\)](#) dated 21.03.2020”. The biosamples will be shared with researchers as per Niti Aayog guidelines (<https://niti.gov.in/sites/default/files/2020-04/Guidelines-for-sharing-of-Biospecimen-and-data-for-research-related-toCOVID-19..pdf>) to conduct research to better understand the COVID-19 disease.

Types of available samples

1. Oropharyngeal swab / throat swab
2. Nasopharyngeal swab / nasal swab
3. Bronchoalveolar lavage
4. Sputum
5. Blood
6. Urine
7. Stool

Limited number of samples from COVID19 negative patients may also be collected and stored for comparative analysis.

Clinical Annotation Form (<https://nlodb.in/pdfs/COVID-19ANNOTATIONFORM.pdf>)